All Informatics articles
-
News10x Genomics launches Atera whole-transcriptome spatial biology platform
The new platform enables researchers to analyse gene expression and cellular organisation within intact tissue at single-cell resolution, supporting large-scale studies across fresh-frozen and FFPE samples. Early adopters include leading research institutions and global service providers, with cloud-based analysis tools and direct sample processing services now available.
-
ArticleThe future of academic core labs: scaling operational excellence without increasing staff
The grounds have shifted the foundations of academic core facilities and the current climate demands their strategic agility in order to thrive. Boyd Butler at Molecular Devices reveals how these labs can capitalise on this opportunity to increase value and efficiency.
-
ArticleBeyond serendipity: rational design and AI’s expansion of the undruggable target landscape
For decades, drugging the ‘undruggable’ was thought to require luck rather than logic. Today, AI is transforming serendipity into strategy by enabling rational, data-driven approaches to previously inaccessible targets.
-
WebinarWhere NAMs stand in early drug discovery: an expert discussion
Register for this webinar to discover the role of NAMs in drug discovery.
-
ArticleOperational data: the hidden driver of faster drug discovery
The key to faster, smarter drug discovery lies in data that’s often overlooked. By exposing hidden delays and inefficiencies, this data enables teams to shorten discovery cycles and progress promising candidates faster.
-
ReportCRISPR & Genomics: Turning Data into Confident Drug Discovery Decisions
Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.
-
NewsNew AI foundation model aims to speed up drug discovery
Insilico Medicine and Liquid AI have partnered to develop a lightweight artificial intelligence foundation model designed to support multiple stages of drug discovery.
-
NewsFlare Therapeutics streamlines drug discovery with Simplicis Ledger
Flare Therapeutics has selected Simplicis Ledger™ as its primary compound and inventory management platform, marking a strategic move toward a more resilient and automated approach to drug discovery.
-
ArticleWhy most labs are not ready for AI: Cenevo shares what must change
Most labs want to use AI, but few have the digital foundations to support it. Cenevo’s leaders explain why progress is slow and what laboratories must fix before AI can deliver real value.
-
ArticleVibe coding 101 for drug discovery scientists
Find out how AI-assisted development is democratising software creation in life sciences.
-
ArticleDrug development in 2026: NAMs, safety and regulatory changes
2026 is set to be a pivotal year for drug discovery, with advances in NAMs and evolving regulatory approaches promising faster, safer early drug development and accelerated delivery of therapies for patients with rare or unmet medical needs.
-
NewsNew generative AI method could make drug discovery faster
A newly developed AI-driven technique could dramatically speed up the discovery of drugs and advanced materials, enabling scientists to design chemically valid, property-targeted molecules in minutes rather than years.
-
NewsHow ageing cells affect brain development and neurodegeneration
New research has revealed how cellular senescence – the process in which ageing cells change function – shapes human brain structure from development to old age, improving our understanding of brain ageing and neurodegenerative diseases.
-
ArticleDisrupting the biologics market through innovations in macrocycle R&D
New macrocycle technologies are turning a once difficult drug class into a scalable engine for developing potent oral therapies.
-
ArticleRethinking drug discovery through transcription factor biology
Complex diseases rarely have single targets. By focusing on transcription factor activity and disease signatures, Scripta Therapeutics is taking a different approach to identifying the drivers of pathology.
-
Article2026: the year AI stops being optional in drug discovery
AI is moving from a supporting role into the core of drug discovery. By 2026, it is expected to shape how targets are chosen, how biology is analysed and how development decisions are made.
-
Newsinsitro expands AI drug discovery with CombinAbleAI acquisition
insitro has acquired Israeli AI therapeutics company CombinAbleAI and launched its TherML platform, creating an end-to-end, modality-agnostic system for designing small molecules, antibodies, oligonucleotides and other complex biologics.
-
ArticleAI steps into drug safety: predicting liver injury earlier than ever before
Drug-induced liver injury remains one of drug development’s most costly pitfalls. Now, AI and transcriptomics may offer a way to spot risks long before they reach patients.
-
NewsSchrödinger partners with Lilly TuneLab on AI drug discovery
Schrödinger has announced a collaboration with Eli Lilly’s TuneLab platform, integrating advanced AI-driven drug discovery workflows into its LiveDesign enterprise informatics system.
-
ArticleWhy tau still lacks treatments and how funders are responding
Tau drives PSP, CBD and other neurodegenerative diseases, yet there are still no disease-modifying treatments. Here, Dr Glenn Harris from the Rainwater Charitable Foundation shares how a coordinated funding effort is supporting basic research to understand tau mechanisms, improve detection and progress therapeutic development.